SeaStar Medical Holding Corporation reported second-quarter 2026 net revenue of $615,000, an 82% increase year over year driven by expanded adoption of its QUELIMMUNE therapy for pediatric acute kidney injury. Six-month net revenue reached $1.1 million, keeping the company on track toward its full-year target of $2 million, while gross margin held at 91%. The company has doubled its hospital customer base to 20 of the 50 premier children's hospitals in the U.S. since the start of 2026, with a year-end goal of 25 hospitals. Enrollment in the NEUTRALIZE-AKI pivotal trial for adult patients reached 223 of 339 targeted patients, with completion expected between the fourth quarter of 2026 and the first quarter of 2027, and a modular PMA submission to the FDA remains targeted for late 2027. Net loss for the quarter was $3.7 million, or $0.91 per share, compared with a net loss of $2.0 million in the prior-year period, and cash and cash equivalents stood at $7.0 million as of June 30, 2026.
SeaStar Medical Holding CorporationRevenue up 82% on expanded adoption of QUELIMMUNE, with hospital customer base doubled.
